新一代口服SERD卡米司群治疗ER阳性、HER2阴性晚期乳腺癌女性的I期剂量递增与扩展试验:SERENA-1单药治疗结果
SERENA-1是一项I期、多部分、开放标签研究,评估卡米司群在ER阳性、HER2阴性晚期乳腺癌女性中的安全性与耐受性。108例患者接受25–450 mg每日一次单药治疗,未观察到≥3级治疗相关不良事件或治疗相关严重不良事件(≤150 mg剂量),确定75、150、300 mg每日一次用于II期试验。
要点
- 卡米司群25–450 mg每日一次单药治疗安全可耐受,≤150 mg剂量无≥3级治疗相关不良事件。
- 最常见治疗相关不良事件为视觉效应(56%)、窦性心动过缓(44%)、疲乏(26%)和恶心(15%)。
- 所有剂量均观察到疗效,包括既往CDK4/6抑制剂和/或氟维司群治疗、基线ESR1突变及内脏转移患者。
核心结论
- 卡米司群是新一代口服选择性雌激素受体拮抗剂和降解剂(SERD)及纯ER拮抗剂,安全性可耐受,药代动力学支持每日一次给药,在经重度既往治疗的患者中显示药效学和临床疗效,无论ESR1突变状态。
研究设计与样本
- SERENA-1(NCT03616587)为I期、多部分、开放标签研究,纳入≥18岁、转移性或复发性ER阳性、HER2阴性乳腺癌女性,对治疗难治或不耐受。
- 患者接受25 mg至450 mg每日一次(剂量递增)或75、150、300 mg每日一次(剂量扩展)卡米司群单药治疗。
- 截至2021年3月9日,108例患者接受卡米司群单药治疗,剂量25–450 mg。
主要发现
- 93例(86.1%)发生治疗相关不良事件,其中82.4%为1级或2级;最常见为视觉效应(56%)、(窦性)心动过缓(44%)、疲乏(26%)、恶心(15%)。
- ≤150 mg剂量下无≥3级治疗相关不良事件或治疗相关严重不良事件。
- 所有研究剂量下中位tmax为给药后约2–4小时,估计半衰期为20–23小时。
- 所有研究剂量均观察到疗效,包括既往接受CDK4/6抑制剂和/或氟维司群治疗、伴或不伴基线ESR1突变、以及内脏疾病包括肝转移的患者。
关键数值与推荐
- 确定75、150、300 mg每日一次剂量用于II期试验(SERENA-2,NCT04214288和SERENA-3,NCT04588298)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: SERENA-1 (NCT03616587) is a phase I, multi-part, open-label study of camizestrant in pre- and post-menopausal women with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. Parts A and B aim to determine the safety and tolerability of camizestrant monotherapy and define doses for clinical evaluation. PATIENTS AND METHODS: Women aged ≥18 years with metastatic or recurrent ER+, HER2- breast cancer, refractory (or intolerant) to therapy, were assigned 25 mg up to 450 mg once daily (QD; escalation) or 75, 150, or 300 mg QD (expansion). Safety and tolerability, antitumor efficacy, pharmacokinetics, and impact on mutations in the estrogen receptor gene (ESR1m) circulating tumor (ct)DNA levels were assessed. RESULTS: By 9 March 2021, 108 patients received camizestrant monotherapy at 25-450 mg doses. Of these, 93 (86.1%) experienced treatment-related adverse events (TRAEs), 82.4% of which were grade 1 or 2. The most common TRAEs were visual effects (56%), (sinus) bradycardia (44%), fatigue (26%), and nausea (15%). There were no TRAEs grade 3 or higher, or treatment-related serious adverse events at doses ≤150 mg. Median tmax was achieved ∼2-4 h post-dose at all doses investigated, with an estimated half-life of 20-23 h. Efficacy was observed at all doses investigated, including in patients with prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) and/or fulvestrant treatment, with and without baseline ESR1 mutations, and with visceral disease, including liver metastases. CONCLUSIONS: Camizestrant is a next-generation oral selective ER antagonist and degrader (SERD) and pure ER antagonist with a tolerable safety profile. The pharmacokinetics profile supports once-daily dosing, with evidence of pharmacodynamic and clinical efficacy in heavily pre-treated patients, regardless of ESR1m. This study established 75-, 150-, and 300-mg QD doses for phase II testing (SERENA-2, NCT04214288 and SERENA-3, NCT04588298).
引用
- Hamilton E, Oliveira M, Turner N, et al. A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results. Ann Oncol. 2024. PMID: 38729567. doi:10.1016/j.annonc.2024.04.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。